Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies

Harbour BioMed brings advanced antibody discovery platforms to the table

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,

Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network

Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network

Novartis to acquire Mariana Oncology for upfront US$ 1 billion

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer

Jubilant Pharmova Singapore to sell its entire 25.8% stake in Sofie Biosciences, USA

JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million

ARTBIO and PharmaLogic inks supply agreement for Lead-212 based Therapeutic Candidate for treatment of prostate cancer

PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology

Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue